Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Riveiro-Barciela M, Barreira-Díaz A, Salcedo MT, Callejo-Pérez A, Muñoz-Couselo E, Iranzo P, Ortiz-Velez C, Cedrés S, Díaz-Mejía N, Ruiz-Cobo JC, Morales R, Aguilar-Company J, Zamora E, Oliveira M, Sanz-Martínez MT, Viladomiu L, Martínez-Gallo M, Felip E, Buti M. Riveiro-Barciela M, et al. Among authors: diaz mejia n. Aliment Pharmacol Ther. 2024 Apr;59(7):865-876. doi: 10.1111/apt.17898. Epub 2024 Feb 7. Aliment Pharmacol Ther. 2024. PMID: 38327102
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate.
Aceituno L, Bañares J, Ruiz-Ortega L, Callejo-Pérez A, Muñoz-Couselo E, Ortiz-Velez C, Díaz-Mejía N, Barreira-Díaz A, Carreras MJ, Farriols A, Buti M, Riveiro-Barciela M. Aceituno L, et al. Among authors: diaz mejia n. Front Med (Lausanne). 2022 Jul 15;9:916213. doi: 10.3389/fmed.2022.916213. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35911389 Free PMC article.
Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study.
Riveiro-Barciela M, Barreira-Díaz A, Callejo-Pérez A, Muñoz-Couselo E, Díaz-Mejía N, Díaz-González Á, Londoño MC, Salcedo MT, Buti M. Riveiro-Barciela M, et al. Among authors: diaz mejia n. Clin Gastroenterol Hepatol. 2023 Mar;21(3):732-740. doi: 10.1016/j.cgh.2022.03.050. Epub 2022 Apr 26. Clin Gastroenterol Hepatol. 2023. PMID: 35487453
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.
Martinez-Marti A, Felip E, Mancuso FM, Caratú G, Matito J, Nuciforo P, Sansano I, Diaz-Mejia N, Cedrés S, Callejo A, Iranzo P, Pardo N, Miquel JM, Navarro A, Vivancos A, Sansó M. Martinez-Marti A, et al. Among authors: diaz mejia n. Br J Cancer. 2021 Nov;125(11):1561-1569. doi: 10.1038/s41416-021-01558-9. Epub 2021 Oct 1. Br J Cancer. 2021. PMID: 34599295 Free PMC article.
PARP inhibitors in advanced prostate cancer: when to use them?
Díaz-Mejía N, García-Illescas D, Morales-Barrera R, Suarez C, Planas J, Maldonado X, Carles J, Mateo J. Díaz-Mejía N, et al. Endocr Relat Cancer. 2021 Jul 15;28(8):T79-T93. doi: 10.1530/ERC-21-0133. Endocr Relat Cancer. 2021. PMID: 34256353 Review.
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores E, Santos-Gallego CG, Diaz-Mejía N, Badimon JJ. Flores E, et al. Among authors: diaz mejia n. Cardiovasc Drugs Ther. 2018 Apr;32(2):213-222. doi: 10.1007/s10557-018-6786-x. Cardiovasc Drugs Ther. 2018. PMID: 29679303 Review.
Lymphoma with massive cardiac involvement.
Flores Umanzor EJ, Caldentey Adrover G, Rodriguez Londres J, San Antonio R, Diaz Mejía NM. Flores Umanzor EJ, et al. Among authors: diaz mejia nm. Acta Cardiol. 2016;71(5):621-622. doi: 10.2143/AC.71.5.3167510. Acta Cardiol. 2016. PMID: 27695024 No abstract available.
Macroglossia and periorbital ecchymosis.
Díaz Mejía NM, Flores Umanzor EJ, Caixal G. Díaz Mejía NM, et al. Eur J Intern Med. 2016 Sep;33:e3-4. doi: 10.1016/j.ejim.2016.02.010. Epub 2016 Feb 20. Eur J Intern Med. 2016. PMID: 26905771 No abstract available.